UK can rule world in advanced gene therapy, says CGT Catapult

Its 2024 annual review demonstrates how, with coherent and concerted action, the UK can take the lead in harnessing the potential of these therapies to deliver life-changing benefits to patients and economic growth to the nation.

It says the advanced therapy industry is at an important stage in its growth. The proof of concept for these therapies has been established, for example with the success of CAR-Ts: As of March 2024, there were 14 indications with an advanced therapy approved and reimbursed in the UK.

Investment in the UK industry has also increased, from £0.77 billion in the financial year ending March 2023 to £0.97bn by March 2024. This return to growth indicates continued confidence in the sector and recognition of its potential, CGT Catapult says.

It adds that the level of investment is closing the gap on the peaks seen in 2021 and 2022 which were fuelled by the COVID-19 pandemic and heightened interest in the life sciences sector.

The review also highlights the changes still needed to unlock the significant benefits of advanced therapies. This includes an acceleration in the emergence of new therapies from the research base; continued development and application of innovative technologies; sufficient infrastructure for manufacturing and delivery; and ensuring there are the systems and skills in place to enable high volume uptake.

Matthew Durdy, Chief Executive of the Cell and Gene Therapy Catapult, said: “At the CGT Catapult, we have worked with the advanced therapies industry from its very early days to its presence today as a valuable and growing industry in the UK.

“We will continue to support the development of the industry, working closely with our partners to ensure that there is an acceleration in the development, manufacturing capability and access to these life-changing therapies over the coming years.”